Description: –
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
Scope of the Report:
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
In 2018, the global Lysosomal Storage Disease (LSD) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
Free Sample Report @ https://www.wiseguyreports.com/enquiry/4000400-global-lysosomal-storage-disease-lsd-market-size-status-and-forecast-2019-2025
The major manufacturers covered in this report
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck
Market segment by Type, the product can be split into
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Lysosomal Storage Disease (LSD) status, future forecast, growth opportunity, key market and key players.
To present the Lysosomal Storage Disease (LSD) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
Leave a Query @ https://www.wiseguyreports.com/enquiry/4000400-global-lysosomal-storage-disease-lsd-market-size-status-and-forecast-2019-2025
Major Key Points in Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type (2014-2025)
1.4.2 Lipid Metabolism Disorder
1.4.3 Glycoprotein Metabolism Disorder
1.5 Market by Application
1.5.1 Global Lysosomal Storage Disease (LSD) Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
…………….
12 International Players Profiles
12.1 Actelion Pharmaceuticals
12.1.1 Actelion Pharmaceuticals Company Details
12.1.2 Company Description and Business Overview
12.1.3 Lysosomal Storage Disease (LSD) Introduction
12.1.4 Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.1.5 Actelion Pharmaceuticals Recent Development
12.2 Amicus Therapeutics
12.2.1 Amicus Therapeutics Company Details
12.2.2 Company Description and Business Overview
12.2.3 Lysosomal Storage Disease (LSD) Introduction
12.2.4 Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.2.5 Amicus Therapeutics Recent Development
12.3 Arena Pharmaceuticals
12.3.1 Arena Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Lysosomal Storage Disease (LSD) Introduction
12.3.4 Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.3.5 Arena Pharmaceuticals Recent Development
12.4 Astellas Pharma
12.4.1 Astellas Pharma Company Details
12.4.2 Company Description and Business Overview
12.4.3 Lysosomal Storage Disease (LSD) Introduction
12.4.4 Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.4.5 Astellas Pharma Recent Development
12.5 Astrazeneca
12.5.1 Astrazeneca Company Details
12.5.2 Company Description and Business Overview
12.5.3 Lysosomal Storage Disease (LSD) Introduction
12.5.4 Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.5.5 Astrazeneca Recent Development
12.6 Biomarin Pharmaceutical
12.6.1 Biomarin Pharmaceutical Company Details
12.6.2 Company Description and Business Overview
12.6.3 Lysosomal Storage Disease (LSD) Introduction
12.6.4 Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.6.5 Biomarin Pharmaceutical Recent Development
12.7 Eli Lilly
12.7.1 Eli Lilly Company Details
12.7.2 Company Description and Business Overview
12.7.3 Lysosomal Storage Disease (LSD) Introduction
12.7.4 Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2014-2019)
12.7.5 Eli Lilly Recent Development
Continued…...
For Detailed Report Visit @ https://www.wiseguyreports.com/reports/4000400-global-lysosomal-storage-disease-lsd-market-size-status-and-forecast-2019-2025
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com